(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover - 2Manual for Wonderful Getaway destination
- 3Venezuelans in Madrid celebrate Maduro's capture
- 4UN panel says Israel operating 'de facto policy of torture'
- 5The most effective method to Oversee Unsold SUVs in the Car Business
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- Could the Star of Bethlehem have actually been a comet?
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- Israel says Iran's military industry will be destroyed 'within days'
- Israel reports killing another senior Iranian oil official
- Expert advice for new stargazers: How to begin your amateur astronomy journey
- Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- The Best Portable Applications for Emotional wellness and Prosperity
